Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device : An Analysis From the ELEVATE Registry. / Gustafsson, Finn; Mirza, Kiran K.; Pya, Yuri; Shaw, Steven; Diegeler, Anno; Netuka, Ivan; Lavee, Jacob; Garbade, Jens; Morshuis, Michiel; Heatley, Jerry; Saeed, Diyar; Potapov, Evgenij; Schmitto, Jan D.; Zimpfer, Daniel; ELEVATE investigators.

I: Journal of Cardiac Failure, Bind 26, Nr. 7, 2020, s. 580-587.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Gustafsson, F, Mirza, KK, Pya, Y, Shaw, S, Diegeler, A, Netuka, I, Lavee, J, Garbade, J, Morshuis, M, Heatley, J, Saeed, D, Potapov, E, Schmitto, JD, Zimpfer, D & ELEVATE investigators 2020, 'Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry', Journal of Cardiac Failure, bind 26, nr. 7, s. 580-587. https://doi.org/10.1016/j.cardfail.2020.04.004

APA

Gustafsson, F., Mirza, K. K., Pya, Y., Shaw, S., Diegeler, A., Netuka, I., Lavee, J., Garbade, J., Morshuis, M., Heatley, J., Saeed, D., Potapov, E., Schmitto, J. D., Zimpfer, D., & ELEVATE investigators (2020). Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry. Journal of Cardiac Failure, 26(7), 580-587. https://doi.org/10.1016/j.cardfail.2020.04.004

Vancouver

Gustafsson F, Mirza KK, Pya Y, Shaw S, Diegeler A, Netuka I o.a. Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry. Journal of Cardiac Failure. 2020;26(7):580-587. https://doi.org/10.1016/j.cardfail.2020.04.004

Author

Gustafsson, Finn ; Mirza, Kiran K. ; Pya, Yuri ; Shaw, Steven ; Diegeler, Anno ; Netuka, Ivan ; Lavee, Jacob ; Garbade, Jens ; Morshuis, Michiel ; Heatley, Jerry ; Saeed, Diyar ; Potapov, Evgenij ; Schmitto, Jan D. ; Zimpfer, Daniel ; ELEVATE investigators. / Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device : An Analysis From the ELEVATE Registry. I: Journal of Cardiac Failure. 2020 ; Bind 26, Nr. 7. s. 580-587.

Bibtex

@article{55917040362a40c7a9ee49f4a782a1b4,
title = "Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry",
abstract = "Background: In patients with a continuous-flow left ventricular assist device, preimplant predictors of poor physical performance are not well-described. We aimed to identify predictors of inability to walk more than 300 m on 6-minute walk test (6MWT) 6 months after HeartMate 3 implantation. Methods and Results: Using data from the European Registry of Patients Implanted With a Full Magnetically Levitated LVAD, patients with available 6MWT at 6 months after implantation were included (N = 194) and grouped according to 6MWT distance (6MWD) of >300 m (n = 150) or 6MWD of <300 m (n = 44). Patients walking <300 m were older (60 ± 10 vs 52 ± 12 years; P <.001), more often New York Heart Association functional class IV (63% vs 42%; P =.03), and more often had type 2 diabetes (43% vs 17%; P <.001) at implantation. Atrial fibrillation was seen in 57% in those with a 6MWT of <300 m vs 31% in those walking longer (P <.002). Further, hemoglobin and estimated glomerular filtration rate was lower in those walking <300 m (both P <.01). In multivariable regression analysis, independent predictors of a 6MWD of <300 m were: atrial fibrillation (odds ratio [OR], 3.22; 95% confidence interval [CI], 1.12–8.67), older age (OR for 10-year increment, 2.81; 95% CI, 1.55–5.07), New York Heart Association functional class IV (OR, 3.37; 95% CI, 1.27–8.98), and Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2 (OR, 6.53; 95% CI, 1.92–22.19). Conclusions: Six months after HeartMate 3 implantation, 77% of patients walked >300 meters in 6 minutes. Apart from age and measures of heart failure severity, atrial fibrillation at implantation is an independent predictor of low 6MWD at 6 months after implantation.",
keywords = "6-minute walk test, Continuous-flow left ventricular assist device, Exercise, Work intolerance",
author = "Finn Gustafsson and Mirza, {Kiran K.} and Yuri Pya and Steven Shaw and Anno Diegeler and Ivan Netuka and Jacob Lavee and Jens Garbade and Michiel Morshuis and Jerry Heatley and Diyar Saeed and Evgenij Potapov and Schmitto, {Jan D.} and Daniel Zimpfer and {ELEVATE investigators}",
year = "2020",
doi = "10.1016/j.cardfail.2020.04.004",
language = "English",
volume = "26",
pages = "580--587",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "7",

}

RIS

TY - JOUR

T1 - Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device

T2 - An Analysis From the ELEVATE Registry

AU - Gustafsson, Finn

AU - Mirza, Kiran K.

AU - Pya, Yuri

AU - Shaw, Steven

AU - Diegeler, Anno

AU - Netuka, Ivan

AU - Lavee, Jacob

AU - Garbade, Jens

AU - Morshuis, Michiel

AU - Heatley, Jerry

AU - Saeed, Diyar

AU - Potapov, Evgenij

AU - Schmitto, Jan D.

AU - Zimpfer, Daniel

AU - ELEVATE investigators

PY - 2020

Y1 - 2020

N2 - Background: In patients with a continuous-flow left ventricular assist device, preimplant predictors of poor physical performance are not well-described. We aimed to identify predictors of inability to walk more than 300 m on 6-minute walk test (6MWT) 6 months after HeartMate 3 implantation. Methods and Results: Using data from the European Registry of Patients Implanted With a Full Magnetically Levitated LVAD, patients with available 6MWT at 6 months after implantation were included (N = 194) and grouped according to 6MWT distance (6MWD) of >300 m (n = 150) or 6MWD of <300 m (n = 44). Patients walking <300 m were older (60 ± 10 vs 52 ± 12 years; P <.001), more often New York Heart Association functional class IV (63% vs 42%; P =.03), and more often had type 2 diabetes (43% vs 17%; P <.001) at implantation. Atrial fibrillation was seen in 57% in those with a 6MWT of <300 m vs 31% in those walking longer (P <.002). Further, hemoglobin and estimated glomerular filtration rate was lower in those walking <300 m (both P <.01). In multivariable regression analysis, independent predictors of a 6MWD of <300 m were: atrial fibrillation (odds ratio [OR], 3.22; 95% confidence interval [CI], 1.12–8.67), older age (OR for 10-year increment, 2.81; 95% CI, 1.55–5.07), New York Heart Association functional class IV (OR, 3.37; 95% CI, 1.27–8.98), and Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2 (OR, 6.53; 95% CI, 1.92–22.19). Conclusions: Six months after HeartMate 3 implantation, 77% of patients walked >300 meters in 6 minutes. Apart from age and measures of heart failure severity, atrial fibrillation at implantation is an independent predictor of low 6MWD at 6 months after implantation.

AB - Background: In patients with a continuous-flow left ventricular assist device, preimplant predictors of poor physical performance are not well-described. We aimed to identify predictors of inability to walk more than 300 m on 6-minute walk test (6MWT) 6 months after HeartMate 3 implantation. Methods and Results: Using data from the European Registry of Patients Implanted With a Full Magnetically Levitated LVAD, patients with available 6MWT at 6 months after implantation were included (N = 194) and grouped according to 6MWT distance (6MWD) of >300 m (n = 150) or 6MWD of <300 m (n = 44). Patients walking <300 m were older (60 ± 10 vs 52 ± 12 years; P <.001), more often New York Heart Association functional class IV (63% vs 42%; P =.03), and more often had type 2 diabetes (43% vs 17%; P <.001) at implantation. Atrial fibrillation was seen in 57% in those with a 6MWT of <300 m vs 31% in those walking longer (P <.002). Further, hemoglobin and estimated glomerular filtration rate was lower in those walking <300 m (both P <.01). In multivariable regression analysis, independent predictors of a 6MWD of <300 m were: atrial fibrillation (odds ratio [OR], 3.22; 95% confidence interval [CI], 1.12–8.67), older age (OR for 10-year increment, 2.81; 95% CI, 1.55–5.07), New York Heart Association functional class IV (OR, 3.37; 95% CI, 1.27–8.98), and Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2 (OR, 6.53; 95% CI, 1.92–22.19). Conclusions: Six months after HeartMate 3 implantation, 77% of patients walked >300 meters in 6 minutes. Apart from age and measures of heart failure severity, atrial fibrillation at implantation is an independent predictor of low 6MWD at 6 months after implantation.

KW - 6-minute walk test

KW - Continuous-flow left ventricular assist device

KW - Exercise

KW - Work intolerance

U2 - 10.1016/j.cardfail.2020.04.004

DO - 10.1016/j.cardfail.2020.04.004

M3 - Journal article

C2 - 32417377

AN - SCOPUS:85086370282

VL - 26

SP - 580

EP - 587

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 7

ER -

ID: 251021583